Pregnane X receptor

PXR was cloned in 1998 by three independent groups, who identified it as a novel orphan nuclear receptor activated by pregnanes and xenobiotics. Its structure features a conserved DNA-binding domain and a ligand-binding domain (LBD) with a large, flexible pocket that accommodates structurally diverse ligands, ranging from bile acids to antibiotics. The LBD's plasticity explains PXR's broad specificity, a key feature for its role as a xenobiotic sensor. PXR forms heterodimers with the retinoid X receptor (RXR) and binds to response elements in target gene promoters.

Upon ligand activation, PXR translocates to the nucleus and upregulates genes encoding phase I enzymes (e.g., CYP3A4, CYP2B6), phase II conjugating enzymes (e.g., UGT1A1, SULT2A1), and phase III transporters (e.g., MDR1, MRP2). This coordinated response enhances the clearance of drugs and toxins, but also underlies many drug–drug interactions, as PXR activation can accelerate the metabolism of co-administered drugs. PXR also modulates bile acid homeostasis and glucose and lipid metabolism, linking xenobiotic sensing to metabolic regulation. Its activity is modulated by coactivators and corepressors, and by post-translational modifications such as phosphorylation.

PXR is a major determinant of individual variability in drug response and toxicity. Polymorphisms in NR1I2 can alter PXR expression or activity, affecting drug metabolism and susceptibility to adverse reactions. PXR activation is implicated in the development of drug resistance in cancer and in the exacerbation of liver injury caused by certain toxins. Conversely, PXR antagonists are being explored as adjuvants to improve chemotherapy efficacy. PXR also plays a role in inflammatory bowel disease and cholestatic liver disease, where its activation can be protective or harmful depending on context.

Beyond its canonical role, PXR exhibits species-specific ligand selectivity: for example, rifampicin activates human PXR but not mouse PXR, while pregnenolone 16α-carbonitrile activates mouse PXR but not human PXR. This has implications for preclinical drug testing. PXR also interacts with the circadian clock, as its expression is regulated by clock genes, and it influences the timing of detoxification. Additionally, PXR has been detected in extrahepatic tissues, including the brain and breast, where it may modulate steroid hormone signaling. Recent research has identified PXR as a potential target for treating non-alcoholic fatty liver disease, as its activation can reduce hepatic lipid accumulation in some models.

Nuclear receptor

A class of transcription factors activated by lipophilic ligands that regulate gene expression.

Xenobiotic

A chemical compound foreign to an organism, such as a drug or pollutant.

CYP3A4

A cytochrome P450 enzyme responsible for metabolizing about half of all drugs.

Retinoid X receptor

A nuclear receptor that forms heterodimers with many other nuclear receptors, including PXR.